Surgical results for small cell lung cancer based on the new TNM staging system

被引:97
作者
Inoue, M
Miyoshi, S
Yasumitsu, T
Mori, T
Iuchi, K
Maeda, H
Matsuda, H
机构
[1] Osaka Univ, Grad Sch Med, Course Intervent Med E1, Dept Surg, Osaka 5650871, Japan
[2] Osaka Prefectural Habikino Hosp, Dept Surg, Osaka, Japan
[3] Natl Kinki Cent Hosp Chest Dis, Dept Surg, Osaka, Japan
[4] Toneyama Natl Hosp, Dept Surg, Osaka, Japan
关键词
D O I
10.1016/S0003-4975(00)01401-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Operation with combined chemotherapy has been recently recommended for very early stage of small cell lung cancer without lymph node metastasis. Methods. A retrospective study was undertaken in 91 patients who had undergone pulmonary resection for small cell lung cancer according to the new international staging system. Results. The 5-year overall probability of survival was 37.1%. The 5-year survival rate was 100% for p-stage 0, 56.1% for p-stage IA, 30.0% for p-stage IB, 57.1% for p-stage IIA, and 42.9% for p-stage IIB. In the p-stage IA-IIB patients who underwent a complete resection, the 5-year survival rate of the patients treated by operation with chemotherapy was better than that of patients treated by operation alone. In addition, the 5-year survival rate of the patients who had four or more courses of chemotherapy was 80.0%. Conclusions. These results suggest that operation should be considered for p-stage IA-IIB patients and more than four courses of combined chemotherapy might be desirable in these resectable cases. (Ann Thorac Surg 2000;70:1615-9) (C) 2000 by The Society of Thoracic Surgeons.
引用
收藏
页码:1615 / 1619
页数:5
相关论文
共 21 条
[1]  
ANGELETTI CA, 1989, EUR J SURG ONCOL, V15, P337
[2]   SURGICAL-TREATMENT OF SMALL-CELL LUNG-CANCER [J].
COOLEN, L ;
VANDENEECKHOUT, A ;
DENEFFE, G ;
DEMEDTS, M ;
VANSTEENKISTE, J .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1995, 9 (02) :59-64
[3]   Surgery for small cell lung cancer [J].
Deslauriers, J .
LUNG CANCER, 1997, 17 :S91-S98
[4]  
FOX W, 1973, LANCET, V2, P63
[5]  
Ginsberg MD, 1997, J CEREBR BLOOD F MET, V17, P1
[6]   INFLUENCE OF SURGICAL RESECTION BEFORE AND AFTER CHEMOTHERAPY ON SURVIVAL IN SMALL-CELL LUNG-CANCER [J].
HARA, N ;
OHTA, M ;
ICHINOSE, Y ;
MOTOHIRO, A ;
KUDA, T ;
ASOH, H ;
KAWASAKI, M .
JOURNAL OF SURGICAL ONCOLOGY, 1991, 47 (01) :53-61
[7]  
Ihde D C, 1984, Cancer, V54, P2722, DOI 10.1002/1097-0142(19841201)54:2+<2722::AID-CNCR2820541419>3.0.CO
[8]  
2-P
[9]   Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide cisplatin followed by cyclophosphamide, doxorubicin, and vincristine [J].
Johnson, BE ;
Bridges, JD ;
Sobczeck, M ;
Gray, J ;
Linnoila, RI ;
Gazdar, AF ;
Hankins, L ;
Steinberg, SM ;
Edison, M ;
Frame, JN ;
Pass, H ;
Nesbitt, J ;
Holden, D ;
Mulshine, JL ;
Glatstein, E ;
Ihde, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :806-813
[10]   SURGERY FOR CURE FOLLOWED BY CHEMOTHERAPY IN SMALL-CELL CARCINOMA OF THE LUNG [J].
KARRER, K ;
ULSPERGER, E .
ACTA ONCOLOGICA, 1995, 34 (07) :899-906